TRDA
Entrada Therapeutics, Inc. NASDAQ Listed Oct 29, 2021$16.03
After hrs
$16.70
+4.18%
Mkt Cap $622.3M
52w Low $4.93
96.4% of range
52w High $16.45
50d MA $12.93
200d MA $9.27
P/E (TTM)
-4.2x
EV/EBITDA
-2.7x
P/B
2.0x
Debt/Equity
0.2x
ROE
-47.0%
P/FCF
-3.3x
RSI (14)
—
ATR (14)
—
Beta
-0.15
50d MA
$12.93
200d MA
$9.27
Avg Volume
192.3K
About
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dy…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -1.32 | -0.94 | +28.8% | 12.79 | +1.1% | -6.7% | -8.7% | -7.3% | -2.3% | -9.1% | — |
| Nov 6, 2025 | AMC | -1.04 | -1.06 | -1.9% | 6.95 | -1.7% | -0.6% | +4.5% | +10.8% | +15.3% | +26.3% | — |
| Aug 6, 2025 | AMC | -0.86 | -1.04 | -20.9% | 5.95 | +0.0% | -10.9% | -12.8% | -15.6% | -13.3% | -10.6% | — |
| May 8, 2025 | AMC | -0.78 | -0.42 | +46.2% | 8.62 | +0.6% | -2.8% | +2.3% | +0.9% | -7.5% | -5.8% | — |
| Feb 27, 2025 | AMC | -0.66 | 0.03 | +104.5% | 11.98 | -1.5% | -0.3% | -5.4% | -8.3% | -11.7% | -13.0% | — |
| Nov 5, 2024 | AMC | -0.67 | -0.35 | +47.8% | 18.62 | +6.1% | +0.2% | +3.3% | +6.4% | +6.8% | +6.3% | — |
| Aug 13, 2024 | AMC | 0.14 | 1.55 | +1007.1% | 15.81 | +1.2% | +0.1% | +2.8% | +4.6% | +4.5% | +7.1% | — |
| May 7, 2024 | AMC | -0.59 | 0.68 | +215.3% | 13.88 | -2.6% | +1.2% | +3.5% | +3.3% | +1.2% | +2.2% | — |
| Mar 13, 2024 | AMC | -0.07 | -0.29 | -314.3% | 12.71 | -2.8% | -4.0% | +0.6% | -2.4% | -0.1% | +5.0% | — |
| Nov 7, 2023 | AMC | -0.74 | 1.02 | +237.8% | 16.99 | +0.1% | -0.7% | -5.2% | -2.1% | -3.5% | -0.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.15 | $13.31 | +1.2% | +5.6% | +5.3% | +8.9% | +6.8% | +2.7% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.02 | $11.01 | -0.1% | +0.2% | +3.5% | +2.5% | +2.5% | +4.2% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.01 | $7.98 | -0.4% | +2.9% | -4.0% | -4.9% | -6.4% | -3.9% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.56 | $9.43 | -1.4% | -5.4% | -8.4% | -7.9% | -16.1% | -16.9% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.85 | $13.04 | +1.5% | -5.7% | -6.5% | -6.8% | -7.1% | -11.8% |
| Feb 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.33 | $13.39 | +0.5% | +1.7% | +5.0% | +1.1% | -2.9% | -3.5% |
| Nov 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $18.62 | $19.75 | +6.1% | +0.2% | +3.3% | +6.4% | +6.8% | +6.3% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.62 | $19.75 | +6.1% | +0.2% | +3.3% | +6.4% | +6.8% | +6.3% |
| Aug 26 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.52 | $16.62 | +0.6% | +2.4% | +1.1% | -1.2% | +5.9% | +7.1% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.81 | $16.00 | +1.2% | +0.1% | +2.8% | +4.6% | +4.5% | +7.1% |
Insider Trades
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Dowden Nathan JOff | President & COO | Sell | 15,000 | $15.33 | $230K | 198,588 | -0.25% | — |
| May 4, 2026 | Sethuraman NatarajanOff | President, Research & Develop. | Sell | 25,907 | $15.39 | $399K | 216,317 | -0.25% | — |
Recent Filings
Data updated apr 27, 2026 5:30am
· Source: massive.com